Similar articles

• Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity.

  Vesikari T, Ruuska T, Green KY, Flores J, Kapikian AZ. Vesikari T, et al. Pediatr Infect Dis J. 1992 Jul;11(7):535-42. doi: 10.1097/00006454-199207000-00006. Pediatr Infect Dis J. 1992. PMID: 1326741 Clinical Trial.
• Rotavirus infections and their prevention by vaccination.

  Vesikari T. Vesikari T. Antiviral Res. 1985;Suppl 1:293-300. doi: 10.1016/s0166-3542(85)80041-3. Antiviral Res. 1985. PMID: 3002263 No abstract available.
• Progress in rotavirus vaccination.

  Vesikari T. Vesikari T. Pediatr Infect Dis. 1985 Nov-Dec;4(6):612-4. doi: 10.1097/00006454-198511000-00002. Pediatr Infect Dis. 1985. PMID: 4080581 No abstract available.
• Perspective on the development and deployment of rotavirus vaccines.

  Edelman R. Edelman R. Pediatr Infect Dis J. 1987 Aug;6(8):704-10. doi: 10.1097/00006454-198708000-00002. Pediatr Infect Dis J. 1987. PMID: 2823210 Review. No abstract available.
• Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a "Jennerian" approach to vaccination.

  Kapikian AZ, Flores J, Hoshino Y, Glass RI, Midthun K, Gorziglia M, Chanock RM. Kapikian AZ, et al. J Infect Dis. 1986 May;153(5):815-22. doi: 10.1093/infdis/153.5.815. J Infect Dis. 1986. PMID: 3009632 Review. No abstract available.